TNF and chronic kidney disease: A single clinical study of MSC‐derived EV therapy in 40 patients with chronic kidney disease was identified.56 Patients receiving EVs had reduced inflammation with increased TGF‐β1 and IL‐10 with reduced tumor necrosis factor (TNF)‐α and improved kidney creatinine clearance compared with placebo‐treated controls.